Analysis of PIK3CA Mutations in the Primary and Recurrent Tumors of Hormone Receptor Positive/human Epidermal Growth Factor Receptor 2 Negative Breast Cancer.

Yue Wang,Xin Li,Shuang Zhang,Li Liang,Ling Xu,Yinhua Liu,Ting Li

DOI: https://doi.org/10.1093/jjco/hyae072

IF: 2.925

2024-01-01

Japanese Journal of Clinical Oncology

Abstract:Objective Our aim was to compare the PIK3CA mutation status in matched primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer (BC) to gain insight into the optimization of patient selection and detection time for PIK3CA-targeted therapy.Methods The data were from 3035 patients with BC diagnosed at the Breast Disease Center, Peking University First Hospital, between January 2008 and December 2017. Matched primary and recurrent samples were profiled using amplification-refractory mutation system-polymerase chain reaction covering 11 mutational hotspots in PIK3CA.Results PIK3CA mutations were detected in 54.3% primary tumors and 48.6% corresponding recurrences. PIK3CA mutation was detected in 37.5% cases in the locoregional recurrent group and 40.0% of distant metastasis, without a statistical difference. Besides, PIK3CA mutations were concordant in 88.6% of the matched pairs. For patients treated with neoadjuvant chemotherapy, 100% concordance was observed. However, PIK3CA mutation was neither correlated with clinicopathological features nor associated with clinical outcomes.Conclusions Mutations in PIK3CA in HR+/HER2- BC generally progressed to recurrent tumors. The high concordance rate of PIK3CA mutation status between primary tumors and corresponding recurrences suggests that the detection of primary tumors could be a substitute approach when recurrent samples are not easily obtainable. The highly consistency of PIK3CA mutation status between primary and recurrent tumors suggests that detecting mutations in primary tumors could substitute for analysis of recurrent samples when they are not easily obtainable.